*Department of Radiation Oncology, Kaiser Permanente Los Angeles Medical Center †Southern California Permanente Medical Group ‡UCLA David Geffen School of Medicine, Los Angeles, CA.
Am J Clin Oncol. 2014 Jun;37(3):255-60. doi: 10.1097/COC.0b013e318271b36a.
To compare the outcomes of skull base meningiomas treated with stereotactic radiosurgery (SRS), hypofractionated stereotactic radiotherapy (hFSRT), and fractionated stereotactic radiotherapy (FSRT).
A total of 220 basal meningiomas in 213 patients were treated using SRS (N=55), hFSRT (N=22), and FSRT (N=143). The median age was 59 years (28 to 84 y). Prior surgery was performed in 74 cases; 39 patients received adjuvant radiotherapy after incomplete resection and 35 patients received salvage radiotherapy after tumor progression. In 146 cases, radiation was the primary therapy. Ten patients had World Health Organization II or III meningiomas.
The median follow-up was 32 months (7 to 97 mo). Median tumor volume was 2.8 cm (0.10 to 16.94 cm), 4.8 cm (0.88 to 20.38 cm), and 11.1 cm (0.43 to 214.00 cm) and the median dose was 1250 cGy in 1 fraction to the 80% isodose line (IDL), 2500 cGy in 5 fractions to the 90% IDL, and 5040 cGy in 28 fractions to the 90% IDL for the SRS, hFSRT, and FSRT groups, respectively. Radiographic control was achieved in 91%, 94%, and 95% (P=0.25), whereas clinical response was seen in 89%, 100%, and 91% (P=0.16) in the SRS, hFSRT, and FSRT groups, respectively.
There is no significant difference in the radiographic and clinical response in patients with skull base meningioma treated with SRS, hFSRT, or FSRT and thus gives the clinician the impetus to tailor treatment techniques to the location and size of the tumor at presentation.
比较立体定向放射外科(SRS)、低分割立体定向放疗(hFSRT)和分割立体定向放疗(FSRT)治疗颅底脑膜瘤的结果。
213 例患者的 220 例颅底脑膜瘤采用 SRS(N=55)、hFSRT(N=22)和 FSRT(N=143)治疗。中位年龄为 59 岁(28-84 岁)。74 例患者行既往手术;39 例患者因不完全切除行辅助放疗,35 例患者因肿瘤进展行挽救性放疗。146 例患者行放疗为初始治疗。10 例患者为世界卫生组织 II 级或 III 级脑膜瘤。
中位随访时间为 32 个月(7-97 个月)。中位肿瘤体积分别为 2.8cm(0.10-16.94cm)、4.8cm(0.88-20.38cm)和 11.1cm(0.43-214.00cm),SRS、hFSRT 和 FSRT 组的中位剂量分别为 1250cGy 至 80%等剂量曲线(IDL)1 次分割、2500cGy 至 90%IDL 5 次分割和 5040cGy 至 90%IDL 28 次分割。SRS、hFSRT 和 FSRT 组的影像学控制率分别为 91%、94%和 95%(P=0.25),临床反应率分别为 89%、100%和 91%(P=0.16)。
SRS、hFSRT 和 FSRT 治疗颅底脑膜瘤的影像学和临床反应无显著差异,这为临床医生提供了根据肿瘤的位置和大小调整治疗技术的动力。